United States securities and exchange commission logo





                 May 31, 2023

       Vu Truong
       Chief Executive Officer
       Aridis Pharmaceuticals, Inc.
       983 University Avenue, Bldg. B
       Los Gatos, California 95032

                                                        Re: Aridis
Pharmaceuticals, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed on May 22,
2023
                                                            File No. 333-272128

       Dear Vu Truong:

               Our initial review of your registration statement indicates that
it fails in numerous
       material respects to comply with the requirements of the Securities Act
of 1933, the rules and
       regulations thereunder, and the requirements of the form. More
specifically, your registration
       statement does not include financial information for the quarterly
period ended March 31, 2023,
       and you are not eligible to incorporate by reference because your Form
10-Q for quarterly period
       ended March 31, 2023, has not been filed.

              We will provide more detailed comments relating to your
registration statement
       following our review of a substantive amendment that addresses these
deficiencies.

              Please contact Dillon Hagius at 202-551-7967 or Laura Crotty at
202-551-7614 with any
       questions.





                 Sincerely,


                 Division of Corporation Finance

                 Office of Life Sciences
       cc:                                              Jeff Fessler